![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Cepheid Achieves FDA Clearance and CLIA Waiver for Flu Assay
Cepheid Achieves FDA Clearance and CLIA Waiver for Flu Assay
January 11, 2018
California-based molecular diagnostic company Cepheid achieved FDA clearance and a Clinical Laboratory Improvement Amendments waiver for its Xpert Xpress Flu test.
The test is indicated for use in near-patient settings for the detection of Flu A and B RNA.
It can be performed using patients’ nasal swabs in under 20 minutes.
Upcoming Events
-
21Oct